Contract manufacturing

We offer contract manufacturing capabilities leveraging the quality, reliability and flexibility of our manufacturing facilities. We operate 29 manufacturing plants across the US, Europe and the MENA region.

Leveraging our high-quality local manufacturing expertise.

For all business development enquiries contact:

US and Canada: usbusinessdevelopment@hikma.com

Europe: EUBusinessDevelopment@hikma.com

MENA:
MENABusinessDevelopment@hikma.com

We offer a broad range of capabilities for oral, nasal and injectable products.

 Injectables 

Dosage forms

    Generics 

Dosage forms

Prefilled syringe

Tablets

IV bags

Capsules

Lyophilised

Nasals

Large parenteral

Oral solutions

Small parenteral

 

Specialised products

Specialised products

Cytotoxic/high containment

High containment

Emulsion

Respiratory

Cephalosporins

Controlled substances

Controlled substances

 

Generics

World class contract manufacturing in Columbus, OH, US
You can call us on 614-308-3500

Injectables

Advanced sterile injectable manufacturing operations in the US and Europe

New

Hikma Pharmaceuticals USA Inc. Extends Voluntary Nationwide Recall of One Lot of Acetaminophen Injection, 1000mg/100mL, ...

Press Release, Product 22 July 2024
New

Hikma Pharmaceuticals Receives Permanent J-Code for COMBOGESIC® IV (acetaminophen and ibuprofen) injection from Centers ...

Press Release, Product 16 July 2024

Notice of results

Press Release, Corporate 15 July 2024

Hikma launches Sodium Acetate Injection, USP, in the US

Press Release, Product 11 July 2024

Hikma – A legacy of quality for a better future

Insight, Corporate 24 June 2024

Hikma acquires Xellia’s differentiated portfolio and enhances Injectables pipeline, manufacturing capabilities and R&D

Press Release, Corporate 17 June 2024

Hikma Pharmaceuticals reaffirms commitment to expanding access to overdose-reversal medicine naloxone at White House mee...

Press Release, Corporate 06 June 2024

Hikma opens new UK office to support NHS supply, strengthening European presence

Press Release, Corporate 03 June 2024

Hikma enters the Spanish generic injectables market, strengthening its European presence

Press Release, Corporate 20 May 2024

Hikma launches Midazolam Injection, USP, in a prefilled syringe in the US

Press Release, Corporate 08 May 2024
Related content

Explore more